Riptide Antimicrobial Research Highlighted on Defense Department Website
July 3, 2018
SAN FRANCISCO, CA. – Riptide’s research supported by the US Department of Defense Medical Research and Development Program (DMRDP) today became the featured program on the Congressionally Directed Medical Research Programs (CDMRP) website. CDMRP cites examples of outstanding research on its website and in the CDMRP Annual Report.
Riptide Addresses JPC-2 Military Expert Review Committee
May 30, 2018
BETHESDA, MD. – On May 29, Riptide Principal Scientist Dr. L. Edward Clemens gave an invited presentation to the JPC-2 Military Infections Disease Research Program (MIDRP) Expert Review Committee, a part of the Congressionally Directed Medical Research Programs (CDMRP).
Riptide Scientific Officer Addresses International Biotechnology and Research Conference
April 26, 2018
ROME, ITALY – Riptide Executive Vice President Dr. Henry Lopez gave today’s keynote address to the “Biotech 2018” International Biotechnology and Research Conference.
RP-185 Featured in 2018 AACR Presentation
April 18, 2018
SAN FRANCISCO, CA. – Riptide Bioscience’s lead drug candidate RP-185 was the subject of an invited poster presentation at this month’s annual meeting of the American Association for Cancer Research (AACR). The AACR meeting is the year’s premier venue for announcing the most significant new research into the etiology and treatment of cancer.
Riptide Bioscience Announces Grant to Develop Advanced Acne Therapeutics
November 2, 2017
SAN FRANCISCO, CA. – Riptide Bioscience, Inc., today announced its receipt of a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, an agency of the National Institutes of Health. The grant is entitled, Designed Antimicrobial Peptides for Treatment of Infectious Acne Vulgaris.
Previous page < Additional articles > Next page